NASDAQ:FHTX

Foghorn Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy FHTX

*Your capital is at risk

$3.64

+0.0100 (+0.275%)

At Close: Jun 03, 2026

Foghorn Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 91.14. In total, the insiders bought 11.69M and sold 1.26M FHTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	91.14
● Buy	11.69M shares
● Sell	1.26M shares
82% Buy Activity Weak Negative Correlation
Buy Signal High Confidence Jan 13, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 91.14. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (82% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 10, 2026 Buy	Common Stock G-Gift	Gottschalk Adrian Chief Executive Officer	CEO / President	59 208 Value: $271.8K
Apr 10, 2026 Sell	Common Stock G-Gift	Gottschalk Adrian Chief Executive Officer	CEO / President	59 208 Value: $0
Apr 09, 2026 Buy	Common Stock G-Gift	Gottschalk Adrian Chief Executive Officer	CEO / President	47 497 Value: $227.5K
Apr 09, 2026 Sell	Common Stock G-Gift	Gottschalk Adrian Chief Executive Officer	CEO / President	47 497 Value: $0
Feb 23, 2026 Buy	Stock Option (right to buy) A-Award	Maynard Ryan D Chief Financial Officer	C-Suite Officer	400 000 Value: $2.30M
Feb 23, 2026 Buy	Common Stock J-Other	Maynard Ryan D Insider	Other	0 Value: $0
Feb 05, 2026 Buy	Stock option (right to buy) A-Award	Gottschalk Adrian Chief Executive Officer	CEO / President	1 075 000 Value: $5.62M
Jan 30, 2026 Buy	Stock Option (right to buy) A-Award	Bellon Steven F. Chief Scientific Officer	Officer	300 000 Value: $1.71M
Jan 30, 2026 Buy	Stock option (right to buy) A-Award	Rivkin Anna Chief Business Officer	Officer	165 000 Value: $942.2K
Jan 30, 2026 Buy	Stock option (right to buy) A-Award	Cardama Alfonso Quintas Chief Medical Officer	Officer	300 000 Value: $1.71M
Jan 30, 2026 Buy	Stock option (right to buy) A-Award	Lacascia Michael Chief Legal Officer	Officer	295 000 Value: $1.68M
Jan 30, 2026 Buy	Stock option (right to buy) A-Award	Costa Carlos Chief People Officer	Officer	230 000 Value: $1.31M
Jan 13, 2026 Buy	Series 2 Warrants to purchase Common Stock A-Award	Flagship Pioneering, Llc	Director	1 117 734 Value: $22.5M
Jan 13, 2026 Buy	Pre-Funded Warrants to purchase Common Stock A-Award	Flagship Pioneering, Llc	Director	2 235 468 Value: $224
Jan 13, 2026 Buy	Series 1 Warrants to purchase Common Stock A-Award	Flagship Pioneering, Llc	Director	1 117 734 Value: $15.0M
Nov 14, 2025 Buy	Common Stock J-Other	Humer Kristian Insider	Other	0 Value: $0
Jun 17, 2025 Buy	Stock Option (right to buy) A-Award	Smith Ian F Director	Director	25 000 Value: $119.8K
Jun 17, 2025 Buy	Stock Option (right to buy) A-Award	Parshall B Lynne Director	Director	25 000 Value: $119.8K
Jun 17, 2025 Buy	Stock Option (right to buy) A-Award	Mendelsohn Michael Director	Director	25 000 Value: $119.8K
Jun 17, 2025 Buy	Stock Option (right to buy) A-Award	Lynch Thomas J. Jr. Director	Director	25 000 Value: $119.8K
Jun 17, 2025 Buy	Stock Option (right to buy) A-Award	Gill Simba Director	Director	25 000 Value: $119.8K
Jun 17, 2025 Buy	Stock Option (right to buy) A-Award	Biller Scott Director	Director	25 000 Value: $119.8K
Jun 17, 2025 Buy	Stock Option (right to buy) A-Award	Cole Douglas G. Director	Director	25 000 Value: $119.8K
Jun 17, 2025 Buy	Stock Option (right to buy) A-Award	Cole Douglas G. Director	Director	25 000 Value: $119.8K
Jun 17, 2025 Buy	Stock Option (right to buy) A-Award	Biller Scott Director	Director	25 000 Value: $119.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT FOGHORN THERAPEUTICS INC.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic...

Read Full Profile Here